Alpha Tau FY26 H1 net loss more than doubled to $68.8 million

• Alpha Tau reported a net loss of USD 68.8 million, or USD 0.76 per share, for the six months ended June 30, 2026.
• Research and development expense climbed to USD 20.9 million from USD 14.2 million a year earlier on higher compensation, trial activity, raw materials.
• Financial expense swung to USD 41.4 million from financial income of USD 315,000, driven by warrant liability remeasurement.
• Cash, cash equivalents, short-term deposits, restricted deposits rose to USD 104.8 million at June 30, 2026, from USD 76.9 million at Dec. 31.
• Tolmar deal included USD 20 million equity investment, USD 15 million for US manufacturing, up to USD 161.5 million milestones; ReSTART enrolled 88 patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608101601PRIMZONEFULLFEED9806721) on August 10, 2026, and is solely responsible for the information contained therein.